1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E03FF66478BABE9A852575830071581F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/creating-an-effective-regulatory-affairs-structure-and-rockville-satellite-office
18
19
2034.237.76.91
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Organizational Strategy and Structure

Creating an Effective Regulatory Affairs Structure and Rockville Satellite Office

ID: 5027


Features:

4 Info Graphics

8 Data Graphics

60 Metrics


Pages/Slides: 15


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Creating an Effective Regulatory Affairs Structure and Rockville Satellite Office"

STUDY OVERVIEW

Behind every successful New Drug Application is an effective relationship involving representatives of the pharmaceutical industry and the U.S. Food and Drug Administration. Across the pharmaceutical industry, both small and large organizations place responsibility for oversight of FDA interactions within Regulatory Affairs.
This study examines what Regulatory Affairs organizational structure works best for interacting with the FDA and how the Regulatory function should lead interactions with the FDA. Additionally, this research explores how some organizations have found success in using a Rockville satellite office as a bridge to building lasting FDA relationships and providing insights on emerging regulatory issues.
Regulatory leaders can use the insights from this research to compare and adjust their group’s structure and how their Regulatory function leads FDA interactions.

KEY TOPICS

  • Executive Summary
  • Effective Organizational Structure for Regulatory Affairs
  • Centralization of the Regulatory Function
  • Role of Rockville Satellite Office

KEY METRICS
  • Top Methods for Working with the FDA
  • Organizational Oversight of FDA Interactions
  • Does Regulatory Structure Mirror FDA Structure
  • Organizational Structure for FDA Interactions
  • Who Oversees Corporate FDA Interactions
  • Importance of Washington/Rockville Office
  • Top Three Activities for Washington/Rockville Office
  • Importance Rating for Rockville Office Activities

SAMPLE KEY FINDINGS
  • No benchmarked companies use a decentralized structure as this would hinder oversight of corporate FDA interactions. Nearly two-thirds of participating companies are highly centralized in how they oversee FDA interactions.
  • A select group of companies that participated in this research see value in using the Rockville office to liaise with the FDA and to gather regulatory intelligence.

METHODOLOGY
The research employed a data gathering approach that gleaned quantitative data from 15 biopharma companies and one medical device company through a detailed survey. In addition, 13 Regulatory leaders participated in in-depth interviews.

Industries Profiled:
Pharmaceutical; Biotech; Chemical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Alcon; Genentech; Bayer; Roche; United Therapeutics; Novartis; AstraZeneca; Bristol-Myers Squibb; Lilly; Boehringer Ingelheim; Amgen; Medtronic; Valeant; Solvay Pharmaceuticals; Merck

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.